Vascular Endothelial Growth Factor A (VEGFA) Antibody

Este producto es parte de VEGFA - Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor A (VEGFA) Antibody

Pida mas información

935106861

info@markelab.com

Precio

292.5€ (80 µl)

Antibody anti-VEGFA

proveedor

Abbexa

reference

abx026640

Tested Applications

ELISA, WB

reactivity

Human

status

RUO

clonality

Polyclonal

Descripción

This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms.


Background

VEGFA is a key member of the vascular endothelial growth factor (VEGF) family and plays a crucial role in angiogenesis, vascular permeability, and endothelial cell proliferation VEGFA binds primarily to its receptors VEGFR-1 and VEGFR-2, triggering signaling pathways like PI3K/AKT and ERK/MAPK to promote blood vessel formation during embryonic development, wound healing, and tissue repair Dysregulated VEGFA expression is associated with pathological angiogenesis observed in cancer, diabetic retinopathy, and age-related macular degeneration (AMD) VEGFA also increases vascular permeability by altering endothelial junctions, contributing to fluid leakage in conditions such as inflammation and tumors Targeted therapies, such as bevacizumab and other anti-VEGF agents, inhibit VEGFA activity to suppress angiogenesis and tumor growth in various cancers and ocular diseases

Características del producto

category

Primary Antibodies


clonality

Polyclonal


reactivity

Human


immunogen target

Vascular Endothelial Growth Factor A (VEGFA)


host

Rabbit


isotype

IgG


conjugation

Unconjugated


form

Liquid


tested applications

ELISA, WB


purification

Purified through a protein A column, followed by peptide affinity purification.


recommended dilution

WB: 1/1000. Optimal dilutions/concentrations should be determined by the end user.


buffer

PBS containing 0.09% sodium azide.


size 1

80 µl


size 2

400 µl


storage

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.


or code

VEGFA


dry ice

No


availability

Shipped within 5-10 working days.


alias

L-VEGF,MVCD1,VEGF,VPF,Vascular permeability factor


Quizá le pueda interesar

Canine VEGF(Vascular Endothelial cell Growth Factor) ELISA Kit

Canine VEGF(Vascular Endothelial cell Growth Factor) ELISA Kit

proveedor

FineTest

reference

ECA0022

reactivity

canine

status

RUO

Precio a consultar

Ver más

Guinea pig VEGF-A(Vascular Endothelial cell Growth Factor A) ELISA Kit

Guinea pig VEGF-A(Vascular Endothelial cell Growth Factor A) ELISA Kit

proveedor

FineTest

reference

EGP0053

reactivity

guinea pig

status

RUO

Precio a consultar

Ver más

Human VEGF(Vascular Endothelial Cell Growth Factor) ELISA Kit

Human VEGF(Vascular Endothelial Cell Growth Factor) ELISA Kit

proveedor

FineTest

reference

EH0327

reactivity

human

status

RUO

Precio a consultar

Ver más